Medicine recalls
|
| |
| Batch recall of Zovirax IV for Intravenous Infusion 250mg |
| |
The Department of Health (DH) today (28 February) endorsed a licensed drug wholesaler, namely GlaxoSmithKline Limited (GSK), to recall one batch (batch number: RN3T) of Zovirax IV for Intravenous Infusion 250mg (Hong Kong Registration number: HK- 18688), from the market as a precautionary measure due to potential quality issue.
The DH received notification from GSK that the overseas manufacturer of the product is initiating a voluntary recall following a complaint reporting glass-like particles in a batch of the above product that was not supplied to Hong Kong. Upon the company’s ongoing investigation, the above batch is considered to have the same potential quality issue. As a precautionary measure, GSK is voluntarily recalling the affected batch of product from the market
The above product, containing aciclovir, is a prescription medicine used for the treatment of Herpes simplex infections and Varicella zoster infections. According to GSK, the above batch of product has been imported into Hong Kong and supplied to the Hospital Authority, local private hospitals and private doctors, and re-exported to Macau.
GSK has set up a hotline (3622 5422) to answer related enquiries.
So far, the DH has not received any adverse reaction reports in connection with the above batch of product. The DH will closely monitor the recall.
Patients who have used the above product should consult their healthcare professionals if in doubt.
End/Friday, February 28, 2025
|
| |
